KIZOO Technology Capital owner Michael Greve discusses recent scientific advancements with Drug Discovery World

DDW-1.0-o

KIZOO Technology Capital owner Michael Greve discusses the recent scientific advancements in addressing the root causes of age-related diseases in the rejuvenation biotechnology sphere—including the work of Underdog Pharmaceuticals. As one of Kizoo’s key startups, Underdog’s goal is to deliver affordable therapeutics for the prevention of heart disease and stroke through the removal of arterial plaque.

Media Contact for Kizoo:

Frank Schueler
Managing Director
Kizoo Technology Capital
fs@kizoo.com

Media Contact for Underdog:

Mike Kope
Co-CEO
Underdog Pharmaceuticals Inc
press@cyclaritytx.com

Cyclarity News:

Cyclarity Therapeutics Announces Clinical Advisory Board

Cyclarity Therapeutics, Inc. today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.

Read More »

KIZOO Technology Capital owner Michael Greve discusses recent scientific advancements with Drug Discovery World

KIZOO Technology Capital owner Michael Greve discusses the recent scientific advancements in addressing the root causes of age-related diseases in the rejuvenation biotechnology sphere—including the work of Underdog Pharmaceuticals. As one of Kizoo’s key startups, Underdog’s goal is to deliver affordable therapeutics for the prevention of heart disease and stroke through the removal of arterial plaque.

Read More »